# Study of Crizotinib for ROS1 and MET Activated Lung Cancer

> **NCT04084717** · PHASE2 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 50 (estimated)

## Conditions studied

- Non-squamous Non-small-cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer
- ROS1 Gene Rearrangement
- MET Activating Mutation
- MET Amplification

## Interventions

- **DRUG:** Crizotinib

## Key facts

- **NCT ID:** NCT04084717
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-12-03
- **Primary completion:** 2024-12
- **Final completion:** 2025-06
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04084717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04084717, "Study of Crizotinib for ROS1 and MET Activated Lung Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04084717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*